Vaccine Development Against Trypanosoma cruzi and Chagas Disease

Juan C. Vázquez-Chagoyán, Shivali Gupta, Nisha Jain Garg

Research output: Chapter in Book/Report/Conference proceedingChapter

46 Scopus citations

Abstract

The pathology of Chagas disease presents a complicated and diverse picture in humans. The major complications and destructive evolutionary outcomes of chronic infection by Trypanosoma cruzi in humans include ventricular fibrillation, thromboembolism and congestive heart failure. Studies in animal models and human patients have revealed the pathogenic mechanisms during disease progression, pathology of disease and features of protective immunity. Accordingly, several antigens, antigen-delivery vehicles and adjuvants have been tested to elicit immune protection to T. cruzi in experimental animals. This review summarizes the research efforts in vaccine development against Chagas disease during the past decade.

Original languageEnglish (US)
Title of host publicationAdvances in Parasitology
PublisherAcademic Press
Pages121-146
Number of pages26
DOIs
StatePublished - 2011

Publication series

NameAdvances in Parasitology
Volume75
ISSN (Print)0065-308X

Keywords

  • Adjuvants
  • Chagas
  • Immunity
  • Therapeutic and prophylactic vaccine
  • Trypanosoma cruzi

ASJC Scopus subject areas

  • Parasitology

Fingerprint Dive into the research topics of 'Vaccine Development Against Trypanosoma cruzi and Chagas Disease'. Together they form a unique fingerprint.

  • Cite this

    Vázquez-Chagoyán, J. C., Gupta, S., & Garg, N. J. (2011). Vaccine Development Against Trypanosoma cruzi and Chagas Disease. In Advances in Parasitology (pp. 121-146). (Advances in Parasitology; Vol. 75). Academic Press. https://doi.org/10.1016/B978-0-12-385863-4.00006-X